All In Biotech

Drug Trial Radar · NCT05486728

Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

A Double-Blinded, Parallel, Vehicle-Controlled Phase 2 Study of SHJ002 Sterile Ophthalmic Solution in Participants With Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

85

Actual

Start

Feb 8, 2023

Primary completion

Dec 7, 2023

Study completion Dec 7, 2023

Sponsor

Lead sponsor
Dreamhawk Vision Biotech, Inc.Industry
Sponsor type
Industry
First posted
Aug 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure efficacy and safety with SHJ002 sterile ophthalmic solution compared to vehicle in participants with Dry Eye Disease (DED). SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

Conditions

  • Dry Eye Disease

Interventions

  • SHJ002/VehicleDrug

    Topical ophthalmic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale)Time frame: Baseline and Day 84

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Australian Eye Specialists

    Werribee, Victoria, Australia

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Kaohsiung, Taiwan

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

  • Ramathibodi Hospital, Mahidol University

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.